Nirogy Therapeutics

Nirogy Therapeutics is a biotechnology company established in 2013 with the aim of pioneering innovative small molecules to disrupt metabolic and immune pathways, advancing therapeutic solutions for cancer and autoimmune diseases. The company's focus lies in creating innovative small molecules to target cellular transporters. Notably, Nirogy Therapeutics has recently made significant progress with a class of small molecules designed to interfere with metabolic and immune processes within the tumor microenvironment. Moreover, the company also has additional platform programs under development to address various disease pathways in oncology and autoimmune diseases. Nirogy Therapeutics recently secured a substantial $16.50M Series A investment on 26 January 2021. This round of funding was led by Santé Ventures and Sporos Bioventures, reflecting a strong vote of confidence in the company's potential and the promise of its innovative approach in addressing critical health challenges. This investment is expected to fuel the company's R&D efforts and further advance its groundbreaking work in disrupting metabolic and immune pathways to combat cancer and autoimmune diseases.